T cells that trigger acute experimental autoimmune encephalomyelitis also mediate subsequent disease relapses and predominantly produce IL-17

Journal of Neuroimmunology

Volumn 230, Issue 1-2, 2011, Pages 26-32

  Li, Jinzhu ^a   Zhao, Xiaoqing ^a   Hao, Hui Wen ^a   Shaw, Michael K ^a   Tse, Harley Y ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adoptive transfer of disease; Cytokine profiles; Experimental autoimmune encephalomyelitis; IL 17; Multiple sclerosis; Remitting relapsing EAE

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; THY 1 ANTIBODY; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HOST CELL; LYMPHOCYTE FUNCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELAPSE; T LYMPHOCYTE; TARGET CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, THY-1; CELL SEPARATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; INTERLEUKIN-17; MICE; RECURRENCE; T-LYMPHOCYTE SUBSETS;

EID: 78650978169     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.08.007     Document Type: Article

References (26)

1. Begolka W.S., Vanderlugt C.L., Rahbe S.M., Miller S.D. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 1998, 161:4437-4446.
2. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., WIekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 342:744-748.
3. Di Rosa F., Francesconi A., Di Virgilio A., Finocchi L., Santilio I., Barnaba V. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis. Eur. J. Immunol. 1998, 28:3893-3903.
4. Hofstetter H.H., Karulin A.Y., Forsthuber T.G., Ott P.A., Tary-Lehmann M., Lehmann P.V. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J. Neuroimmunol. 2005, 170:105-114.
5. Jone R.E., Bourdette D., Moes N., Vandenbark A., Zamora A., Offner H. Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis. J. Immunol. 2003, 170:1690-1698.
6. Kim C., Tse H.Y. Adoptive transfer of murine experimental autoimmune encephalomyelitis in SJL. Thy-1congenic mouse strains. J. Neuroimmunol. 1993, 46:129-136.
7. Kroenke M.A., Segal B.M. Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2007, 85:1685-1693.
8. Lublin F., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
9. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.-C., Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction afftect dominant effector category. J. Exp. Med. 2008, 205:799-810.
10. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 1995, 182:75-85.
11. Mokhtarian F., McFarlin D.E., Raine C.S. adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature 1984, 309:356-358.
12. Segal B.M. Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in aprototypical Th1-mediated autoimmune disease. Curr. Allergy Asthma Rep. 2003, 3:86-93.
13. Shaw M.K., Kim C., Hao H.W., Chen F., Tse H.Y. Induction of myelin basic protein-specific experimental autoimmune encephalitis in C57BL/6 mice. Mapping of T cell epitopes and T cell receptor Vβ gene segment usage. J. Neurosci. Res. 1996, 45:690-699.
14. Shi G., Ramaswamy M., Vistica B.P., Cox C.A., Tan C., Wawrousek E.F., Siegel R.M., Gery I. Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J. Immunol. 2009, 183:7547-7556.
15. Skundric D.S., Kim C., Tse H.Y., Raine C.S. Homing of T cells to the central nervous system throughout the course of relapsing experimental autoimmune encephalomyelitis in Thy-1 congenic mice. J. Neuroimmunol. 1993, 46:113-122.
16. Skundric D.S., Huston K., Shaw K., Tse H.Y., Raine C.S. Experimental allergic encephalomyelitis: T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain. Lab. Invest. 1994, 71:671-679.
17. Steinman L. Absence of "Original Antigenic Sin" in autoimmunity provides an unforeseen platform for immune therapy. J. Exp. Med. 1999, 189:1021-1024.
18. Steinman L. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed [with a hedge on this bet]. J. Autoimmun. 2000, 14:278-282.
19. Suryani S., Sutton I. An interferon-γ-producing Th1 subset is the major source of IL-17 in experimental autoimmune encephalitis. J. Neuroimmunol. 2007, 183:96-103.
20. Takacs K., Chandler P., Altmann D.M. Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread. Eur. J. Immunol. 1997, 27:2927-2934.
21. Traugott U., Raine C.S., McFarlin D.E. Acute experimental allergic encephalomyelitis in the mouse: immunopathology of the developing lesion. Cell. Immunol. 1985, 91:240-254.
22. Tuohy V.K., Yu M., Yin L., Kawczak J.A., Kinkel R.P. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 1999, 189:1033-1042.
23. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: Implications for immunotherapy. Nat. Rev. 2002, 2:85-95.
24. Vanderlugt C.L., Neville K.L., Nikcevich K.M., Eager T.N., Bluestone J.A., Miller S.D. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 2000, 164:670-678.
25. Xiao B.G., Ma C.G., Xu L.Y., Link H., Lu C.Z. IL-12/IFN-gamma/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol. Immunol. 2008, 45:1191-1196.
26. Yu M., Johnson J.M., Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 1996, 183:1777-1788.